HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages
- 1 November 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 18 (11) , 1671-1678
- https://doi.org/10.1161/01.atv.18.11.1671
Abstract
—Macrophages secrete matrix metalloproteinases (MMPs) that may weaken the fibrous cap of atherosclerotic plaque, predisposing its fissuration. The 92-kDa gelatinase B (MMP-9) has been identified in abdominal aortic aneurysms and in atherosclerotic tissues. Fluvastatin, through the inhibition of the isoprenoid pathway, inhibits major processes of atherogenesis in experimental models (smooth muscle cell migration and proliferation and cholesterol accumulation in macrophages). We studied the effect of fluvastatin on the activity of MMP-9 in mouse and human macrophages in culture. Conditioned media of cells treated for 24 hours with fluvastatin were analyzed by gelatin zymography. In mouse macrophages, fluvastatin (5 to 100 μmol/L) significantly inhibited in a dose-dependent manner MMP-9 activity from 20% to 40% versus control. The drug, at a concentration as low as 5 μmol/L, inhibited MMP-9 activity (≈30%) in human monocyte–derived macrophages as well. Phorbol esters (TPA, 50 ng/mL) stimulated MMP-9 activity by 50%, and fluvastatin inhibited this enhanced activity up to 50% in both mouse and human macrophages. The above results on the secretion of MMP-9 were confirmed by Western blotting and ELISA. The inhibitory effect of fluvastatin was overcome by the simultaneous addition of exogenous mevalonate (100 μmol/L), a precursor of isoprenoids. Fluvastatin’s effect was fully reversible, and the drug did not cause any cellular toxicity. The statin did not block directly the in vitro activation of the secreted protease. Similar data were obtained with simvastatin. Altogether, our data indicate an inhibition of MMP-9 secretion by the drug. This effect is mediated by the inhibition of synthesis of mevalonate, a precursor of numerous derivatives essential for several cellular functions.Keywords
This publication has 28 references indexed in Scilit:
- The extracellular matrix and atherosclerosisCurrent Opinion in Lipidology, 1995
- Can Atherosclerotic Coronary Arteries Vasodilate? An Intraoperative High-Frequency Epicardial Echocardiographic StudyThe American Journal of Cardiology, 1995
- Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque ruptureJournal of the American College of Cardiology, 1994
- Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophagesAtherosclerosis, 1993
- Induction of collagenase and stromelysin gene expression by mechanical injury in a vascular smooth muscle‐derived cell lineJournal of Cellular Physiology, 1993
- Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitroJournal of Cellular Physiology, 1993
- Inhibition of Matrix Metalloproteinase 9 Activation by a Specific Monoclonal AntibodyHybridoma, 1993
- Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductaseAtherosclerosis, 1993
- Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.Heart, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993